文献速递瓣膜病与结构性心脏病

低水平与高水平B型利钠肽均与保留射血分数TAVR患者死亡率升高相关

Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry.
PubMed 文献 · Eur Heart J · 2020-01-01

基于PARTNER II试验与注册研究,纳入1782例症状性重度主动脉瓣狭窄且LVEF≥50%接受TAVR的患者,分析基线BNP与2年结局的关系。调整后样条曲线显示log-BNP与全因及心血管死亡呈非线性关联,最低和最高值均与死亡率升高相关。与正常BNP相比,低水平和显著升高BNP与全因死亡增加独立相关。

要点

  • TAVR术前BNP与2年死亡呈U型关系,低值和极高值均提示风险升高。
  • 基线BNP正常(50-<100 pg/mL)者2年全因死亡率最低,为9.8%。
  • 低BNP(<50 pg/mL)调整后全因死亡HR 2.6(95%CI 1.3-5.0,P=0.005)。

核心结论

  • 在重度症状性AS且LVEF≥50%接受TAVR的患者中,低水平和显著升高BNP均与2年全因及心血管死亡率升高相关。

研究设计与样本

  • PARTNER II试验与注册研究的分析,共纳入1782例接受TAVR的症状性重度AS且LVEF≥50%的患者。
  • BNP按连续log转换值及预设分类(低<50、正常≥50且<100、中度升高≥100且<400、显著升高≥400 pg/mL)评估。
  • 采用Kaplan-Meier事件率和多变量Cox比例风险回归比较出院至2年的临床结局。

主要发现

  • 调整后样条曲线显示log-BNP与全因及心血管死亡呈非线性关联,最低和最高值均与死亡率升高相关。
  • 低(n=86)、正常(n=202)、中度升高(n=885)、显著升高(n=609)BNP组2年全因死亡率分别为20.0%、9.8%、17.7%、26.1%。
  • 与正常BNP相比,低BNP调整后全因死亡HR 2.6(95%CI 1.3-5.0,P=0.005)。
  • 与正常BNP相比,显著升高BNP调整后全因死亡HR 2.1(95%CI 1.3-3.5,P=0.003)。
  • 与正常BNP相比,中度升高BNP调整后全因死亡HR 1.6(95%CI 1.0-2.6,P=0.06)。

关键数值与推荐

  • BNP分类阈值:低<50 pg/mL,正常≥50且<100 pg/mL,中度升高≥100且<400 pg/mL,显著升高≥400 pg/mL。

临床怎么用

  • TAVR术前评估BNP时,应同时关注低水平与显著升高,二者均提示2年死亡风险增加。
  • BNP正常(50-<100 pg/mL)者预后相对较好,可作为风险分层参照。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: B-type natriuretic peptide (BNP) is a cardiac neurohormone that is secreted in response to ventricular volume expansion and pressure overload. There are conflicting data regarding the association between BNP levels and outcomes after transcatheter aortic valve replacement (TAVR). We therefore sought to assess the association between baseline BNP and adverse outcomes in patients with symptomatic, severe aortic stenosis (AS), and left ventricular ejection fraction (LVEF) ≥50%, undergoing TAVR in the PARTNER 2 Trial and Registry. METHODS AND RESULTS: A total of 1782 patients were included in the analysis, and BNP was evaluated both as a continuous log-transformed value and by a priori categories: low (<50 pg/mL), normal (≥50 and <100 pg/mL), moderately elevated (≥100 and <400 pg/mL), or markedly elevated (≥400 pg/mL). Clinical outcomes from discharge to 2 years were compared between patients according to their baseline BNP level, using Kaplan-Meier event rates and multivariable Cox proportional hazards regression models. After adjustment, spline curves revealed a non-linear association between log-transformed BNP and all-cause and cardiovascular mortality in which both the lowest and highest values were associated with increased mortality. Two-year all-cause mortality rates for those with low (n = 86), normal (n = 202), moderately elevated (n = 885), and markedly elevated (n = 609) baseline BNP were 20.0%, 9.8%, 17.7%, and 26.1%, respectively. In adjusted models, compared to a normal baseline BNP, low [adjusted hazard ratio (HR) 2.6, 95% confidence interval (CI) 1.3-5.0, P-value 0.005], moderately elevated (adjusted HR 1.6, 95% CI 1.0-2.6, P-value 0.06), and markedly elevated (adjusted HR 2.1, 95% CI 1.3-3.5, P-value 0.003) BNP were associated with increased all-cause mortality, driven by cardiovascular mortality. CONCLUSIONS: In a large cohort of patients with severe symptomatic AS and preserved LVEF undergoing TAVR, all-cause and cardiovascular mortality rates at 2 years were higher in patients with low and markedly elevated BNP levels. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/ unique identifier #NCT01314313, #NCT02184442, #NCT03222128, and #NCT03222141.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Chen S, Redfors B, O'Neill BP, et al. Low and elevated B-type natriuretic peptide levels are associated with increased mortality in patients with preserved ejection fraction undergoing transcatheter aortic valve replacement: an analysis of the PARTNER II trial and registry. Eur Heart J. 2020. PMID: 31883339. doi:10.1093/eurheartj/ehz892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。